Effects of isoflavones in peritoneal dialysis patients
Phase 2
Recruiting
- Conditions
- End stage of renal disease.Chronic kidney disease, stage 5N18.5
- Registration Number
- IRCT20091116002716N4
- Lead Sponsor
- ational Nutrition and Food Technology Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Continuous Ambulatory Peritoneal Dialysis for 6 months or more
Body mass index below 35
Exclusion Criteria
infections; inflammatory diseases
liver diseases
past medical history of cancer
receiving glucocorticoid and anti-inflammatory drugs
receiving isoflavone supplements
Constant consumption of soy or foods containing soy in the diet
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum concentrations of glucose. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzymatic method.;Serum concentrations of fructoseamine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of carboxymethyl lysine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of pentosidine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Systolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways do isoflavones modulate to reduce hypertension and AGEs in ESRD patients?
How does isoflavone supplementation compare to standard antihypertensive therapies in stage 5 CKD patients?
Which biomarkers correlate with isoflavone efficacy in lowering fructoseamine in peritoneal dialysis populations?
What adverse events are associated with isoflavone use in ESRD patients and how are they managed?
Are there synergistic effects of combining isoflavones with SGLT2 inhibitors in mitigating oxidative stress in CKD?